Global
About

Committed to the development
of innovative single domain antibody drugs

About Novamab
Committed to becoming the world's leading R&D enterprise of innovative single domain antibody drugs

Novamab, located in Zhoupu International Medical Park, Pudong New Area, Shanghai, is a clinical stage biopharmaceutical company dedicated to the development of innovative sdAb drugs.

With a solid foundation in sdAb research and development for more than 10 years, Novamab has established the first and only sdAb development platform covering the full biopharmaceutical process in China. The philosophy of Novamab is "to build itself into a global leading Bio-Tech enterprise focusing on respiratory and autoimmune diseases, aiming to bring safer, more effective and more convenient therapeutic drugs to the patients all over the world.

Novamab was founded in October 2017. At present, it has built a research and development and production base of more than 7500 square meters and a camel breeding base. Novamab has independently created five core technology platforms: sdAb rapid screening platform, Pichia pastoris based CMC platform, biologcial drug inhalation platform, long-acting sdAb platform and bispecific sdAb platform. Each platform has unique leading technology, which makes it more competitive.The powerful paltform make it possible to rapidly bring the candidates to commercialization. The completion of the 500L GMP workshop for sdAb production using Pichia pastoris fills the industry gap in this field, which is extremely scarce and competitive.

2017
Novamab was founded
60+
Number of employees
7500m2
R&D and production base and camel breeding base
500L
GMP workshop for sdAb production using Pichia pastoris
About Novamab
Mission&Vision
Mission
Develop life-changing therapeutic drugs for patients through innovative sdAb research to make treatment more convenient and effective
Vision
Antibody from camel starts a healthy future
About Novamab
Company philosophy

The company concept can be started from the company name. The word nova in Novamab comes from Latin, meaning new, meaning "new". Mab is the abbreviation of monoclonal antibody, so Novamab means new antibody, while the development of sdAb has only been more than 20 years, and it is also a new antibody in the field of antibody research and development, so the two correspond to each other.


The "Y" shape in the company's icon represents the structural shape of the sdAb that lacks the light chain, and echoes with the sdAb again; In addition, the circular part of the icon is similar to a shield, indicating our desire and determination to defend human health, while the stars symbolize our good expectations for sdAb and ourselves. We hope that camel (camel and Luo) antibody can become a new star in the field of antibody medicine and start human future health.

About Novamab
Founder
Dr. Yakun Wan
Founder, Chairman and CEO

Dr. Yakun Wan, founder and CEO of Novamab, has 17 years of sdAb research experience and is a leading figure in the field. He previously worked at the Shanghai Institute of Pharmaceutical Research, Chinese Academy of Sciences, and Southeast University, and directed the Jiangsu Nanoantibody Engineering Technology R&D Center. Dr. Wan also conducted postdoctoral research at the University of Texas at Austin, Baylor College of Medicine, and the American Institute of Systems Biology.

Dr. Wan has been honored with several awards, such as the "Hundred Talents Plan" by Shanghai Institute of Medicine, the Six Talent Peak Plans by Jiangsu Province, the "High-level Creative Talents Plan" by the Ministry of Education, and the "New Century Excellent Talents" award. He was also acknowledged as an "Outstanding Innovation and Entrepreneurship Talent" in 2021 and a "Pudong New Area Pearl Talent Leader" in 2024. Under his guidance, Novamab was recognized as one of China's top 50 innovative pharmaceutical enterprises in 2020 and a top 100 innovative seed enterprise in 2022.

Dr. Wan has authored over 70 scientific papers, with over 50 as first or corresponding author in SCI-indexed journals. He holds over 110 invention patents, 45 of which are authorized, and has led projects funded by the Shanghai Science and Technology Innovation Fund and the National Natural Science Foundation, among others.

Dr. Wan founded China's first sdAb R&D team in drug development, partnering with top pharmaceutical firms to progress several products to clinical phases. Novamab, with a complete R&D, pilot testing, and GMP production system, is uniquely positioned to handle full-process sdAb development in China. The 500L Pichia pastoris GMP pilot production workshop fills a significant industry void. Dr. Wan's team created the world's first inhaled nanobody drugs, LQ036 and LQ043H, targeting IL-4R and TSLP, respectively. These drugs are intended for patients with moderate-to-severe asthma, providing rapid local effects and low toxicity.